Introduction
Peritoneal dissemination is a common pattern of metastasis in patients with advanced or recurrent gastric cancer. Patients with malignant ascites are at a particularly high risk for rapid exacerbation of general condition, leading to poor outcomes.
The JCOG 0106 study was a randomized phase III trial designed to establish whether sequential therapy with methotrexate and 5-fluorouracil (FU) was superior to a continuous intravenous infusion of 5-FU alone as first-line chemotherapy in patients who had advanced or recurrent gastric cancer with peritoneal dissemination 1) . The median survival time was 10.6 months in the methotrexate plus 5-fluorouracil group, as compared with 9.4 months in the infusional 5-FU group (p = 0.31). Combination of Methotrexate and 5-FU could not have shown superior effect compared to 5-FU therapy. Standard treatment for advanced or recurrent gastric cancer with peritoneal dissemination was therefore, has not been determined to date.
Recent clinical studies in patients with advanced or recurrent gastric cancer have included the JCOG9912 2) and the SPIRITS trials 3) . On the basis of these studies, S-1 and cisplatin was established to be the standard therapy for advanced gastric cancer in Japan. Quite a few studies have reported that taxane derivatives are effective for the management of gastric cancer with peritoneal dissemination [4] [5] [6] [7] . A good response to taxanes is primarily attributed to two factors. First, taxanes are particularly effective against undifferentiated type carcinomas, which are often accompanied by peritoneal dissemination [8] [9] . Second, the penetration of taxanes into the peritoneum is high 10) . However, subgroup analysis to reconfirm the hypothesis for patients with peritoneal dissemination and ascites was not performed in either the JCOG 9912 or SPIRITS trial. In this study, the efficacy and safety of combined chemotherapy with S-1, an oral FU, and docetaxel, a taxane, in patients who had advanced or recurrent gastric cancer with peritoneal dissemination and ascites, those usually lead an extremely poor prognosis.
Methods
The subjects were 5 patients with advanced or re- 2 ) was given as an intravenous infusion on day 1 (Fig. 1) . Treatment was repeated at 3-week intervals and continued until the detection of progressive disease or the onset of unacceptable adverse events.
Tumor responses were evaluated on the basis of the results of upper gastrointestinal series and computed tomography. The Response Evaluation Criteria in Solid Tumors (RECIST 1.1) was used to assess antitumor response. The survival time was calculated as the interval from the date of starting treatment to the date of death. The survival rate was calculated by the Kaplan-Meier method. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria, version 2.0.
Results
We studied 3 men and 2 women with a mean age of 61 years (range, 58 to 77). The performance status was 0 in 1 patient and 1 in 4 patients. The histopathological diagnosis was signet-ring cell carcinoma in 2, poorly differentiated adenocarcinoma in 1, papillary adenocarcinoma in 1, and tubular adenocarcinoma in 1 patient ( Table 1) .
As for tumor response, 3 patients had a partial response, 1 had stable disease, and 1 had progressive disease. The overall response rate was 60%. All patients who responded to treatment had diffuse-type, i.e. signet ring cell carcinoma and poorly differentiated gastric cancer ( Table 2 ). The median number of treatment courses was 4 (range, 2 to 7), the median time to treatment failure was 235 days (range, 80 to 346), and the median survival time was 315 days (range, 109 to 558) (Fig. 2) . Four patients were subsequently given second-line treatment: 2 received S-1, 1 received S-1 plus cisplatin, and 1 received weekly paclitaxel. The 1-year survival rate was 20% (Table 3) . Table 4 shows adverse events according to grade. Grade 3 or 4 adverse events were leukopenia in 2, neutropenia in 1, diarrhea in 1, and nausea in 1 patient.
Discussion
In Japan, the JCOG9912 trial established S-1 to be a key drug for the standard, first-line chemotherapy for advanced or recurrent gastric cancer 1) . Combining S-1 with various types of anticancer agents that have different mechanisms of action has been shown to produce high response rates. S-1 combined with drugs such as cisplatin, irinotecan, or taxanes have been evaluated in phase III studies 2, 8, 9, 11) . The SPIRITS trial already demonstrated that cisplatin enhances the effectiveness of S-1 2) . In contrast, the GC0301/TOP-002 study failed to show that S-1 plus irinotecan was more effective than S-1 alone 11) . Patient enrollment has just been completed in a phase III study examining whether docetaxel enhances the effectiveness of S-1 (START). The results of analysis are awaited.
First-line chemotherapy for advanced or recurrent gastric cancer associated with peritoneal dissemination and malignant ascites remains to be clarified by more robust evidence. Treatment strategies must therefore be based on the results of the phase III trials mentioned above and other studies. Overall, 49% of the patients in the JCOG 9912 trial and 29% of those in the SPIRITS trial had peritoneal dissemination. The results of these phase III studies may provide important clues to the development of new treatment strategies. However, the results of these studies must be interpreted cautiously because the eligibility criteria excluded patients with high-grade peritoneal dissemination. S-1 has been reported to be effective for diffuse-type gastric cancer, frequently associated with peritoneal dissemination and malignant ascites 12) . Many studies have reported that taxane derivatives are effective against peritoneal dissemination and malignant ascites 8, 9) and that high concentrations of taxanes are transferred to the peritoneum 10) . In particular, docetaxel acts cytotoxically by promoting tubulin polymerization and inhibiting its depolymerization. Docetaxel has been experimentally shown to act synergistically with S-1 13, 14) . In fact, the V325 study demonstrated that docetaxel enhances the effectiveness of standard therapy 15) . A phase II study of docetaxel combined with S-1 obtained an overall response rate of 60.0% in patients who had advanced or recurrent gastric cancer with disseminated peritoneal metastases 16) . Many patients with peritoneal dissemination and malignant ascites have disseminated metastases to the kidney and ureter, frequently precluding the use of cisplatin because of concern about potential adverse effects on renal function. We consider S-1 plus docetaxel to be the treatment of choice in such patients. Our experience suggests that that combined chemotherapy with S-1 and docetaxel has a low incidence of adverse events and can be administered safely.
In our study, patients who responded to the treatment with S-1 and docetaxel showed improved prognosis. The median survival time was 315 days (10.5 months) and, that could be considered as one of the best results for that stage of the disease. All patients with responses had diffuse-type gastric cancer. Our results suggest that S-1 combined with docetaxel is effective and safe in patients with diffuse-type gastric cancer. We consider combined chemotherapy with S-1 and docetaxel to be a safe and promising treatment with a low incidence of adverse events in patients who have severe advanced or recurrent gastric cancer with malignant ascites and peritoneal dissemination, S-1 plus docetaxel may contribute to improve survival even in this subgroup of patients. 
